Wenshi Wang, MD, PhD

Wen­shi Wang brings both inter­na­tion­al and Amer­i­can insti­tu­tion­al drug devel­op­ment expe­ri­ence to her role at Metageno­mi, with expe­ri­ence in var­i­ous roles in Ger­many, City of Hope, USC Keck, Children’s Hos­pi­tal Los Ange­les, Mof­fit Can­cer Insti­tute and Kite Pharma. 

Wenshi Wang, MD, PhD's profile photo

VP of Cell Therapy Development

Most recent­ly, Wen­shi served as Senior Direc­tor at Sang­amo Ther­a­peu­tics lead­ing the cell ther­a­py phar­ma­ceu­ti­cal devel­op­ment depart­ment for CAR-Treg, gene mod­i­fied CD34 and iPSC plat­form devel­op­ment. At Kite Phar­ma, Wen­shi con­tributed devel­op­ment process and assay devel­op­ment for IND fil­ing on CAR T and TCR T prod­ucts. She has made sig­nif­i­cant con­tri­bu­tions to many suc­cess­ful fil­ings with agen­cies (Inter­act, Pre-IND, IND/​IMPD, Pre-BLA).

Wen­shi has near­ly a decade’s expe­ri­ence in pre-clin­i­­cal, phase I, II and III inves­ti­ga­tions and bio­mark­ers stud­ies at Mof­fitt Can­cer Cen­ter and the Uni­ver­si­ty of South­ern California.

Wen­shi holds a PhD in Micro­bi­ol­o­gy & Immunol­o­gy from Huazhong Sci­ence & Tech­nol­o­gy Uni­ver­si­ty, Chi­na and a MD in Clin­i­cal Med­i­cine from Tian­jin Med­ical Uni­ver­si­ty. She also has a U.S. Patent for her Bio­mark­er work.